Login to Your Account



Pieris, Stelis ink anticalin development pact

By Cormac Sheridan
Staff Writer

Tuesday, December 17, 2013

Completing its second Indian deal this quarter, Pieris AG entered a pact with Stelis Biopharma Pvt. Ltd., a subsidiary of Bangalore-based Strides Arcolab Ltd., to develop two anticalin-based protein drugs, primarily for ophthalmology indications. Financial terms were not disclosed, but the deal has a similar structure to the partnership it entered in October with Zydus Cadila Ltd., of Ahmedabad.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription